Connected for a Cure: Precision Oncology in the Age of AI and Data-Driven Collaboration
The upcoming online event on August 6, 2025, features oncology and technology leaders Allan Jordan and Alister Campbell discussing how AI, centralized high-quality data, and cross-organizational collaboration are revolutionizing precision oncology research and drug discovery by enabling faster, smarter therapeutic innovation and operationalizing AI-ready infrastructure in biotech and pharma R&D.
Join a conversation with Allan Jordan (VP of Oncology, Sygnature Discovery) and Alister Campbell (VP of Science & Technology, Dotmatics), hosted by Lauren Brown (Senior Account Executive, Dotmatics).
Together, they explore how oncology research is evolving in the face of AI, data deluge, and global collaboration, highlighting real-world lessons from leading research partnerships and what it takes to transform insights into impact in today’s landscape.
Designed for biotech and pharma leaders, this session focuses on how to operationalise data-driven R&D and bring AI-readiness to the front lines of drug discovery.
Key Takeaways
- Data as the Differentiator: Why high-quality, accessible, and centralized data is now a prerequisite for therapeutic innovation.
- Collaboration Without Compromise: How cross-organizational data sharing is fueling breakthroughs once thought impossible, like targeting KRAS.
- AI with Impact: Real-world examples of how AI is accelerating the drug design cycle, optimizing trial matching, and reshaping early diagnosis.
- AI-Ready Infrastructure: What your organization needs today to ensure tomorrow’s success—from clinical pipelines to internal decision-making.
Secure your spot for this discussion on the future of oncology R&D. Gain clarity on how leading teams are using collaborative data and AI to move faster, smarter, and more effectively toward treating the most complex diseases of our time.
Featured Speakers
- Allan Jordan, VP of Oncology, Sygnature Discovery
- Alister Campbell, VP Science & Technology, Dotmatics
- Lauren Brown, Senior Account Executive, Dotmatics
Event Details
- Date: August 6, 2025
- Time: 12PM EST
- Location: Online
Related
U.S. News & World Report: How AI is Transforming Medicine and Patient Care
A U.S. News & World Report article highlights how AI-driven platforms like Dotmatics Luma are revolutionizing healthcare and life sciences by enabling scientists to efficiently manage large datasets, accelerate drug discovery, and enhance patient care through real-time data integration and decision-making.
NBC Louisiana: How AI is Accelerating Drug Discovery
In an NBC Louisiana feature, Dotmatics’ VP Phil Mounteney explained how AI is revolutionizing drug discovery by significantly reducing development time from up to ten years to potentially half, enhancing efficiency in analyzing vast data sets while ensuring data privacy by keeping sensitive information secure and in-house.
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.
NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development
In an NBC Las Vegas interview, Phil Mounteney, VP of Science and Technology at Dotmatics, explains how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines for faster and more efficient medical breakthroughs post-COVID.
Gray TV Washington DC: AI helping scientists make drug breakthroughs
The Gray TV Washington DC feature highlights how scientists, including Christian Olsen of Dotmatics, are leveraging AI and machine learning to accelerate drug discovery and expedite bringing new drugs to market.